Top Page
Beamtree Holdings Ltd
(Sydney:BMT)
Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)
Beamtree Holdings Ltd Business Overview & Revenue Model
Beamtree Holdings Ltd Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 27.60M | 22.77M | 19.09M | 8.39M | 4.12M | Gross Profit |
| 4.89M | 2.14M | 2.34M | 2.77M | 2.65M | EBIT |
| -609.00K | -7.01M | -5.94M | -1.03M | 188.04K | EBITDA |
| -331.00K | -1.24M | -2.28M | 1.02M | 697.11K | Net Income Common Stockholders |
| -5.11M | -6.91M | -4.45M | -383.62K | 382.90K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 5.04M | 8.81M | 6.35M | 14.12M | 4.20M | Total Assets |
| 59.65M | 62.53M | 63.91M | 47.05M | 32.22M | Total Debt |
| 1.66M | 755.00K | 1.12M | 799.36K | 44.27K | Net Debt |
| -3.38M | -8.05M | -5.23M | -13.32M | -4.16M | Total Liabilities |
| 12.52M | 15.31M | 15.33M | 4.96M | 3.01M | Stockholders Equity |
| 47.14M | 47.22M | 48.58M | 42.09M | 29.22M |
| Cash Flow | Free Cash Flow | |||
| -4.51M | -1.88M | -4.83M | -2.64M | -26.13K | Operating Cash Flow |
| -492.00K | 768.00K | -2.32M | 240.65K | 1.05M | Investing Cash Flow |
| -4.02M | -2.65M | -5.16M | -2.98M | -849.49K | Financing Cash Flow |
| 749.00K | 4.34M | -286.00K | 12.65M | -128.49K |
Beamtree Holdings Ltd Technical Analysis
Beamtree Holdings Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$56.40B | 28.14 | 25.23% | 1.32% | 10.54% | 38.69% | |
57 Neutral | AU$89.96M | ― | -11.80% | ― | 14.56% | 13.36% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
| $11.57B | 46.93 | 20.61% | 1.54% | ― | ― | ||
61 Neutral | AU$17.47M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
53 Neutral | AU$691.16M | ― | -112.97% | ― | ― | -84.82% | |
52 Neutral | AU$259.11M | ― | -0.87% | 7.82% | 14.24% | -109.59% |
Beamtree Holdings Ltd Corporate Events
Beamtree Holdings Limited has announced a proposed issue of 350,000 fully paid ordinary securities, scheduled for July 1, 2025. This move is part of a placement or other type of issue, which will be quoted on the ASX, potentially impacting the company’s market presence and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced the issuance of 375,000 fully paid ordinary shares without disclosure to investors under Part 6D.2 of the Corporations Act. This move is in compliance with relevant provisions of the Corporations Act, and there is no excluded information as per sections 708A(7) and 708A(8). This announcement reflects Beamtree’s ongoing commitment to adhering to regulatory standards while potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced the quotation of 375,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code BMT. This move is part of the company’s strategy to enhance its market presence and provide more liquidity to its shareholders, potentially impacting its market positioning positively.
The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced a strategic partnership with the NHS Confederation to expand its presence in the UK healthcare market. This collaboration aims to replicate Beamtree’s successful ANZ membership model within the NHS hospital sector in England, Wales, and Northern Ireland. The partnership will establish a benchmarking collaborative, providing NHS trusts with access to advanced analytics, benchmarking services, and peer-to-peer learning communities. The initial contract is for five years, with an option to extend, and includes a significant investment by Beamtree to establish the platform in the UK. This move is a key part of Beamtree’s growth strategy, offering potential benefits to NHS trusts through enhanced data analytics and operational benchmarking.
The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced significant progress in its operations for the third quarter of FY25, highlighted by major contract wins and strategic developments. The company has launched the Evolve Collaborative with NHS Confederation in England, renewed a contract in Ireland, and expanded its market presence in Saudi Arabia and the UK. These developments are expected to significantly increase Beamtree’s market share and annual recurring revenue, positioning the company for improved profitability and positive cash generation by the end of FY25.
Beamtree Holdings Limited has announced strategic contract wins for its autonomous coding technology with Barwon Health in Australia, Milton Keynes University NHS Foundation Trust in the UK, and a leading health sciences medical center in Canada. These contracts, while not financially material, signify a strategic milestone for Beamtree, showcasing the demand for its AI technology in key markets and marking the conversion of its sales pipeline as outlined in their first-half reporting.
Beamtree Holdings Limited has secured three new contracts in Australia, the UK, and Canada for its autonomous coding product, valued at approximately $0.6 million annually. These contracts highlight the demand for Beamtree’s AI technology in key markets and mark a strategic achievement that supports the company’s growth and innovation in healthcare data solutions.